It is well established that a range of pro-inflammatory cytokines is upregulated in the mucosa of IBD patients in remission, potentially resulting in downregulated FXR activity, leading to the observed reduced SHP expression in the current study [33]. Here, NR0B2 is linked to inflammatory bowel disease.